Sílvia Castro Coelho1, Gabriela M Almeida2,3, Filipe Santos-Silva2,4,5,6, Maria Carmo Pereira1, Manuel A N Coelho1. 1. a LEPABE, Department of Chemical Engineering, Faculty of Engineering , University of Porto , Porto , Portugal. 2. b Instituto de Investigação e Inovação em Saúde , Universidade do Porto , Porto , Portugal. 3. c Expression Regulation in Cancer Group , IPATIMUP , Porto , Portugal. 4. d Public Awareness of Cancer Unit , IPATIMUP , Porto , Portugal. 5. e Faculty of Medicine , University of Porto , Porto , Portugal. 6. f Department of Biochemistry and Molecular Biology, Eppley Institute , University of Nebraska Medical Center , Omaha , NE , USA.
Abstract
OBJECTIVES: Gold nanoparticles have become promising vectors for cancer diagnosis and treatment. The present study investigates the effect of bortezomib (BTZ), a proteasome inhibitor, conjugated with pegylated gold nanoparticles (PEGAuNPs) in pancreatic and lung cancer cells. METHODS: Synthesized gold nanoparticles (PEGAuNPs) were conjugated with bortezomib antitumor drug. We investigated the cytotoxicity induced by BTZ conjugated with functionalized gold nanoparticles in vitro, in the human pancreatic (S2-013) and lung (A549) cancer cell lines. RESULTS: We found an efficient of conjugation of BTZ with PEGAuNPs. In vitro assays showed that after 72 h' incubation with PEGAuNPs-BTZ cancer cells revealed alterations in morphology; also for S2-013 and A549 cancer cells, the IC50 value of free BTZ is respectively 1.5 and 4.3 times higher than the IC50 value of PEGAuNPs-BTZ. Furthermore, for TERT-HPNE, the IC50 value is around 63 times lower for free BTZ than the conjugated nanovehicle. Cell growth inhibition results showed a remarkable enhancement in the effect of BTZ when conjugated with AuNPs. CONCLUSIONS: Our findings showed that conjugation with PEGAuNPs enhance the BTZ growth-inhibition effect on human cancer cells (S2-013 and A549) and decreases its toxicity against normal cells (TERT-HPNE).
OBJECTIVES: Gold nanoparticles have become promising vectors for cancer diagnosis and treatment. The present study investigates the effect of bortezomib (BTZ), a proteasome inhibitor, conjugated with pegylated gold nanoparticles (PEGAuNPs) in pancreatic and lung cancer cells. METHODS: Synthesized gold nanoparticles (PEGAuNPs) were conjugated with bortezomib antitumor drug. We investigated the cytotoxicity induced by BTZ conjugated with functionalized gold nanoparticles in vitro, in the humanpancreatic (S2-013) and lung (A549) cancer cell lines. RESULTS: We found an efficient of conjugation of BTZ with PEGAuNPs. In vitro assays showed that after 72 h' incubation with PEGAuNPs-BTZcancer cells revealed alterations in morphology; also for S2-013 and A549 cancer cells, the IC50 value of free BTZ is respectively 1.5 and 4.3 times higher than the IC50 value of PEGAuNPs-BTZ. Furthermore, for TERT-HPNE, the IC50 value is around 63 times lower for free BTZ than the conjugated nanovehicle. Cell growth inhibition results showed a remarkable enhancement in the effect of BTZ when conjugated with AuNPs. CONCLUSIONS: Our findings showed that conjugation with PEGAuNPs enhance the BTZ growth-inhibition effect on humancancer cells (S2-013 and A549) and decreases its toxicity against normal cells (TERT-HPNE).
Entities:
Keywords:
Bortezomib; gold nanoparticles; lung cancer; pancreatic cancer
Authors: G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta Journal: Pharmacol Ther Date: 2020-05-19 Impact factor: 12.310
Authors: Bailee H Sliker; Benjamin T Goetz; Haley L Peters; Brittany J Poelaert; Gloria E O Borgstahl; Joyce C Solheim Journal: Cancer Biol Ther Date: 2019-02-27 Impact factor: 4.742
Authors: Eliseo Carrasco-Esteban; José Antonio Domínguez-Rullán; Patricia Barrionuevo-Castillo; Lira Pelari-Mici; Olwen Leaman; Sara Sastre-Gallego; Fernando López-Campos Journal: J Clin Transl Res Date: 2021-03-16